Item 8.01 Other Events.

As previously disclosed, on August 7, 2015, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into a license and collaboration agreement with AstraZeneca. Under the agreement, AstraZeneca acquired exclusive rights to the Company’s immunotherapy product candidate, now known as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. Within the broader collaboration, AstraZeneca also gained rights to co-develop up to two new DNA-based cancer vaccine product candidates. Under the terms of the agreement, AstraZeneca made an upfront payment of $27.5 million to the Company, and the Company was eligible to receive potential future payments of up to $700 million in the aggregate for MEDI0457 and these two new candidates upon reaching specified development, regulatory and commercial milestones. The total potential future milestone payments related to MEDI0457 are approximately $250 million in the aggregate. The other potential future milestone payments are subject to on-going evaluations by AstraZeneca with respect to the development of the two new product candidates and may never be received by the Company. Under the collaboration agreement, AstraZeneca continues to fund all development costs, and the Company is eligible to receive up to double-digit tiered royalties on product sales of MEDI0457 as well as potential royalties on product sales of the other product candidates that are the subject of the collaboration. The Company has updated its company presentation, which is available on its corporate website, to provide this additional information.

Caution Concerning Forward Looking Statements

This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about expectations regarding the clinical development of the Company’s product candidates, including those being developed in collaboration with AstraZeneca. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties inherent in the conduct of the Company’s collaboration with AstraZeneca and the initiation and conduct of future clinical trials. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2019, the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2019, and in the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.